We are a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders.

Our website has been developed to help share our expertise on the interaction of light and human skin as well as provide a thorough overview of our global drug development programs.

CLINUVEL’s lead compound, SCENESSE^® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe.

In December 2014 the European Commission granted SCENESSE^® marketing authorisation under exceptional circumstances for the prevention of phototoxicity in adult patients with EPP.

In October 2019, the US FDA granted CLINUVEL marketing approval for SCENESSE^® (afamelanotide 16mg) to increase pain free light exposure in adult patients with a history of phototoxic reactions from EPP.

Further trials of SCENESSE^® are underway in the pigmentary disorder vitiligo.